Gaois

This is a static copy of data that is exported from IATE on an occasional basis. It should not be assumed that information provided about an entry here will always correspond to the current version of the entry in IATE. That current version can be checked by clicking on the link on the upper right hand side of each entry. More information »

1 result

  1. SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine

    #665658

    IATE #3599598
    vacsaín nanacháithníní spícephróitéine athchuingreach SARS-CoV-2 Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    SARS-CoV-2 recombinant spike protein nanoparticle vaccine
    en
    Definition recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant Reference "Cheryl Keech, M.D., Ph.D., Gary Albert, M.S., Iksung Cho, M.S., Andreana Robertson, M.S., Patricia Reed, B.S., Susan Neal, Joyce S. Plested, Ph.D., Mingzhu Zhu, Ph.D., Shane Cloney-Clark, B.S., Haixia Zhou, Ph.D., Gale Smith, Ph.D., Nita Patel, M.S., Matthew B. Frieman, Ph.D., Robert E. Haupt, M.S., James Logue, B.A., Marisa McGrath, B.A., Stuart Weston, Ph.D., Pedro A. Piedra, M.D., Chinar Desai, B.S., Kathleen Callahan, M.S., Maggie Lewis, M.S., Patricia Price-Abbott, M.S., Neil Formica, M.B., B.S., Vivek Shinde, M.D., Louis Fries, M.D., Jason D. Lickliter, M.B., B.S., Ph.D., Paul Griffin, M.D., Bethanie Wilkinson, Ph.D., and Gregory M. Glenn, M.D., 'Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine' (18.6.2021), New England Journal of Medicine 2020; 383:2320-2332"
    NVX-CoV2373
    mul